Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04497168 · ClinicalTrials.gov registry record · Phase 2
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT04497168 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 58 participants.
The verdict
NCT04497168, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.
Interventions
- DRUG Placebo
- DRUG Citalopram 20mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2026-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04497168
The ClinicalTrials.gov registry entry for NCT04497168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04497168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04497168 about?
NCT04497168 is a clinical study titled "Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease". This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.
What is the current status of trial NCT04497168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2021-04-01. Estimated completion is 2026-03-02.
What interventions are being tested in trial NCT04497168?
The interventions under investigation include: Placebo (DRUG), Citalopram 20mg (DRUG).
Who is sponsoring clinical trial NCT04497168?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.